Alnylam Pharmaceuticals (ALNY) Work In Process (2018 - 2026)

Alnylam Pharmaceuticals (ALNY) has 9 years of Work In Process data on file, last reported at $59.0 million in Q2 2026.

• Quarterly Work In Process rose 34.87% year-over-year to $59.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $59.0 million (up 34.87% YoY) and the FY2025 annual result came in at $65.1 million, changed 0.22% from the prior year.
• Work In Process retreated to $59.0 million in Q2 2026, from $65.5 million in the prior quarter.
• In the past five years, Work In Process ranged from a high of $116.7 million in Q2 2023 to a low of $35.5 million in Q3 2025.
• A 5-year average of $77.9 million and a median of $73.0 million in 2024 frame the typical range for Work In Process.
• Annual changes were most pronounced in 2022 — Work In Process surged 295.84% — and 2025, when it plunged 49.18%.
• Tracing ALNY's Work In Process over 5 years: stood at $113.8 million in 2022, then slumped by 32.36% to $77.0 million in 2023, then dropped by 15.57% to $65.0 million in 2024, then grew by 0.22% to $65.1 million in 2025, then fell by 9.33% to $59.0 million in 2026.
• The last three Work In Process figures came in at $59.0 million (Q2 2026), $65.5 million (Q1 2026), and $65.1 million (Q4 2025), per Business Quant data.